Dr. Riedell on Unique Data Points from an Analysis in MCL

Video

In Partnership With:

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma (MCL).

Several unique data points were noted from the analysis, Riedell explains. For example, the data showed that when employing a multivariate analysis, the effect of relapse on overall survival (OS) varied with time, Riedell says. Additionally, the effect of relapse was the greatest at early time points after patients had undergone an autologous hematopoietic cell transplant (AHCT), Riedell explains. Moreover, patients who relapsed by the 6-, 12-, or 18-month landmark time points following AHCT had the worst outcomes overall, Riedell says.

Moreover, patients aged 60 years or older had worse OS at the various landmark time points compared with younger patients, which is consistent with other previously published data, Riedell concludes.

Related Videos
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD